How Psychedelic Treatment Through Canada’s SAP Works
Two psychedelic industry insiders reflect on the progress and flaws within Health Canada’s recent amendment to the Special Access Program.
Two psychedelic industry insiders reflect on the progress and flaws within Health Canada’s recent amendment to the Special Access Program.
CEO Christopher Dawson and COO Andrew Galloway spent years working in clinical mental health treatment centers before betting big on psychedelics and ancient healing methods.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.